Enliven Therapeutics (ELVN) Revenue & Revenue Breakdown
Enliven Therapeutics Revenue Highlights
00
Enliven Therapeutics Revenue by Period
Enliven Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2018-12-31 | - | - |
Enliven Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | - | 100.00% |
2024-06-30 | - | 100.00% |
2024-03-31 | - | -100.00% |
2023-12-31 | $440.00K | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | 100.00% |
2023-03-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2019-09-30 | - | 100.00% |
2019-06-30 | - | 100.00% |
2019-03-31 | - | - |
Enliven Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
KRON | Kronos Bio | $6.29M | $2.37M |
INBX | Inhibrx Biosciences | $1.80M | - |
LYRA | Lyra Therapeutics | $1.56M | $195.00K |
CGEM | Cullinan Oncology | - | - |
GPCR | Structure Therapeutics | - | - |
IMRX | Immuneering | - | - |
GOSS | Gossamer Bio | - | $9.48M |
AVTE | Aerovate Therapeutics | - | - |
REPL | Replimune Group | - | - |
ELYM | Eliem Therapeutics | - | - |
PMVP | PMV Pharmaceuticals | - | - |
CELC | Celcuity | - | - |
MACK | Merrimack Pharmaceuticals | - | - |
NVCT | Nuvectis Pharma | - | - |
ELVN | Enliven Therapeutics | - | - |
CMPX | Compass Therapeutics | - | - |
MLTX | MoonLake Immunotherapeutics | - | - |